210 related articles for article (PubMed ID: 32878237)
1. Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib.
Yamashita Y; Morita S; Hosoi H; Kobata H; Kishimoto S; Ishibashi T; Mishima H; Kinoshita A; Backes BJ; Yoshiura KI; Papa FR; Sonoki T; Tamura S
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878237
[TBL] [Abstract][Full Text] [Related]
2. Allosteric Inhibition of c-Abl to Induce Unfolded Protein Response and Cell Death in Multiple Myeloma.
Kosako H; Yamashita Y; Morita S; Iwabuchi S; Hashimoto S; Matsuoka TA; Sonoki T; Tamura S
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555805
[TBL] [Abstract][Full Text] [Related]
3. Profiling of Unfolded Protein Response Markers and Effect of IRE1α-specific Inhibitor in Pituitary Neuroendocrine Tumor.
Morita S; Uraki S; Ariyasu H; Tsuji T; Doi A; Furuta H; Yamoto T; Nakao N; Akamizu T; Matsuoka TA
Endocrinology; 2024 Feb; 165(4):. PubMed ID: 38289718
[TBL] [Abstract][Full Text] [Related]
4. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Mimura N; Fulciniti M; Gorgun G; Tai YT; Cirstea D; Santo L; Hu Y; Fabre C; Minami J; Ohguchi H; Kiziltepe T; Ikeda H; Kawano Y; French M; Blumenthal M; Tam V; Kertesz NL; Malyankar UM; Hokenson M; Pham T; Zeng Q; Patterson JB; Richardson PG; Munshi NC; Anderson KC
Blood; 2012 Jun; 119(24):5772-81. PubMed ID: 22538852
[TBL] [Abstract][Full Text] [Related]
5. Disruption of IRE1α through its kinase domain attenuates multiple myeloma.
Harnoss JM; Le Thomas A; Shemorry A; Marsters SA; Lawrence DA; Lu M; Chen YA; Qing J; Totpal K; Kan D; Segal E; Merchant M; Reichelt M; Ackerly Wallweber H; Wang W; Clark K; Kaufman S; Beresini MH; Laing ST; Sandoval W; Lorenzo M; Wu J; Ly J; De Bruyn T; Heidersbach A; Haley B; Gogineni A; Weimer RM; Lee D; Braun MG; Rudolph J; VanWyngarden MJ; Sherbenou DW; Gomez-Bougie P; Amiot M; Acosta-Alvear D; Walter P; Ashkenazi A
Proc Natl Acad Sci U S A; 2019 Aug; 116(33):16420-16429. PubMed ID: 31371506
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibition of IRE1α kinase/RNase has anti-fibrotic effects in the lung.
Thamsen M; Ghosh R; Auyeung VC; Brumwell A; Chapman HA; Backes BJ; Perara G; Maly DJ; Sheppard D; Papa FR
PLoS One; 2019; 14(1):e0209824. PubMed ID: 30625178
[TBL] [Abstract][Full Text] [Related]
7. Reduced response of IRE1α/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
Xu X; Liu J; Huang B; Chen M; Yuan S; Li X; Li J
Tumori; 2017 May; 103(3):261-267. PubMed ID: 27647225
[TBL] [Abstract][Full Text] [Related]
8. Targeting of BCR-ABL1 and IRE1α induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.
Vieri M; Preisinger C; Schemionek M; Salimi A; Patterson JB; Samali A; Brümmendorf TH; Appelmann I; Kharabi Masouleh B
Carcinogenesis; 2021 Feb; 42(2):272-284. PubMed ID: 32915195
[TBL] [Abstract][Full Text] [Related]
9. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
10. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells.
Gao Q; Li XX; Xu YM; Zhang JZ; Rong SD; Qin YQ; Fang J
Cancer Lett; 2020 Apr; 476():67-74. PubMed ID: 32061752
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Targeting of IRE1 in Cancer.
Raymundo DP; Doultsinos D; Guillory X; Carlesso A; Eriksson LA; Chevet E
Trends Cancer; 2020 Dec; 6(12):1018-1030. PubMed ID: 32861679
[TBL] [Abstract][Full Text] [Related]
12. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma.
Papandreou I; Denko NC; Olson M; Van Melckebeke H; Lust S; Tam A; Solow-Cordero DE; Bouley DM; Offner F; Niwa M; Koong AC
Blood; 2011 Jan; 117(4):1311-4. PubMed ID: 21081713
[TBL] [Abstract][Full Text] [Related]
13. Kinase Photoaffinity Labeling Reveals Low Selectivity Profile of the IRE1 Targeting Imidazopyrazine-Based KIRA6 Inhibitor.
Korovesis D; Rufo N; Derua R; Agostinis P; Verhelst SHL
ACS Chem Biol; 2020 Dec; 15(12):3106-3111. PubMed ID: 33290055
[TBL] [Abstract][Full Text] [Related]
14. Ethyl Acetate Extract of
Chou CK; Liu W; Hong YJ; Dahms HU; Chiu CH; Chang WT; Chien CM; Yen CH; Cheng YB; Chiu CC
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933620
[TBL] [Abstract][Full Text] [Related]
15. Heat Shock Protein 47 Maintains Cancer Cell Growth by Inhibiting the Unfolded Protein Response Transducer IRE1α.
Yoneda A; Sakai-Sawada K; Minomi K; Tamura Y
Mol Cancer Res; 2020 Jun; 18(6):847-858. PubMed ID: 32102897
[TBL] [Abstract][Full Text] [Related]
16. Identification of autophosphorylation inhibitors of the inositol-requiring enzyme 1 alpha (IRE1α) by high-throughput screening using a DELFIA assay.
Newbatt Y; Hardcastle A; McAndrew PC; Strover JA; Mirza A; Morgan GJ; Burke R; Davies FE; Collins I; van Montfort RL
J Biomol Screen; 2013 Mar; 18(3):298-308. PubMed ID: 23139381
[TBL] [Abstract][Full Text] [Related]
17. KIRA8 attenuates non-alcoholic steatohepatitis through inhibition of the IRE1α/XBP1 signalling pathway.
Zhao S; Liu X; Li L; Kong X; Sun W; Loomes K; Nie T; Hui X; Wu D
Biochem Biophys Res Commun; 2022 Dec; 632():158-164. PubMed ID: 36209584
[TBL] [Abstract][Full Text] [Related]
18. Opposite Roles of RNase and Kinase Activities of Inositol-Requiring Enzyme 1 (IRE1) on HSV-1 Replication.
Su A; Wang H; Li Y; Wang X; Chen D; Wu Z
Viruses; 2017 Aug; 9(9):. PubMed ID: 28832521
[TBL] [Abstract][Full Text] [Related]
19. IRE1α drives lung epithelial progenitor dysfunction to establish a niche for pulmonary fibrosis.
Auyeung VC; Downey MS; Thamsen M; Wenger TA; Backes BJ; Sheppard D; Papa FR
Am J Physiol Lung Cell Mol Physiol; 2022 Apr; 322(4):L564-L580. PubMed ID: 35170357
[TBL] [Abstract][Full Text] [Related]
20. IRE1α is critical for Kaempferol-induced neuroblastoma differentiation.
Abdullah A; Talwar P; d'Hellencourt CL; Ravanan P
FEBS J; 2019 Apr; 286(7):1375-1392. PubMed ID: 30719816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
